C12N 2810/85
Mammalian
Official title: mammalian
C12N2810/85 (Mammalian) appears on 253 US grants and 380 published applications in this corpus.
Search patents in C12N- Granted patents
- 253
- Published applications
- 380
- Assignees
- 202
- Inventors
- 722
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 2 | 0 |
| 1997 | 1 | 0 |
| 1998 | 5 | 0 |
| 1999 | 8 | 0 |
| 2000 | 4 | 0 |
| 2001 | 6 | 3 |
| 2002 | 12 | 12 |
| 2003 | 11 | 24 |
| 2004 | 6 | 17 |
| 2005 | 7 | 15 |
| 2006 | 10 | 20 |
| 2007 | 4 | 16 |
| 2008 | 8 | 19 |
| 2009 | 9 | 12 |
| 2010 | 10 | 21 |
| 2011 | 5 | 16 |
| 2012 | 8 | 22 |
| 2013 | 12 | 9 |
| 2014 | 18 | 21 |
| 2015 | 13 | 16 |
| 2016 | 11 | 24 |
| 2017 | 12 | 13 |
| 2018 | 10 | 20 |
| 2019 | 17 | 11 |
| 2020 | 11 | 11 |
| 2021 | 5 | 12 |
| 2022 | 5 | 9 |
| 2023 | 7 | 7 |
| 2024 | 4 | 11 |
| 2025 | 7 | 11 |
| 2026 | 5 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2810/859From immunoglobulinsIndexing code114
- C12N 2810/855From receptorsIndexing code81
- C12N 2810/851From growth factorsIndexing code40
- C12N 2810/852From cytokinesIndexing code20
- C12N 2810/854From hormonesIndexing code18
- C12N 2810/857From blood coagulation or fibrinolysis factorsIndexing code11
- C12N 2810/858From apolipopeptidesIndexing code6
Recent patents
- Methods of delivering anionic agents in vivo using non-viral nanoparticle-based delivery systems16 Jun 2026US 12,653,905 B2Nanora Pharma Inc.
- Ligand discovery and gene delivery via retroviral surface display19 May 2026US 12,631,621 B2Massachusetts Institute of Technology
- Ligand discovery and gene delivery via retroviral surface display19 May 2026US 12,631,622 B2Massachusetts Institute of Technology
- Oncolytic tumor viruses and methods of use6 Jan 2026US 12,514,887 B2The Salk Institute for Biological Studies
- Recombinant nucleic acid construct6 Jan 2026US 12,516,348 B2PANTHERNA THERAPEUTICS GmbH
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Modified aav particles16 Jul 2026US 2026/0200989 A1Hoffmann-La Roche Inc.
- Il13ra2-targeting herpes simplex virus and anti-il13ra2 antibody or antigen-binding fragment thereof11 Jun 2026US 2026/0159594 A1The University of Tokyo
- Adapter-based retroviral vector system for the selective transduction of target cells7 May 2026US 2026/0125703 A1Miltenyi Biotec GmbH
- Therapeutic recombinant viruses16 Apr 2026US 2026/0103727 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
Most cited
By later US patents
- TAL effector-mediated DNA modification216US 8,440,431 B2Iowa State University Research Foundation, Inc. · 2013
- Virus vectors and methods of making and administering the same197US 7,172,893 B2The University of North Carolina at Chapel Hill · 2007
- Tal effector-mediated DNA modification187US 8,440,432 B2Iowa State University Research Foundation, Inc. · 2013
- TAL effector-mediated DNA modification186US 8,450,471 B2Iowa State University Research Foundation, Inc. · 2013
- Recombinant parvovirus vectors and method of making167US 6,491,907 B1The University of North Carolina at Chapel Hill · 2002